Cargando…
Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC
Hepatocellular carcinoma is a cancer with increasing incidence and largely refractory to current anticancer drugs. Since Sorafenib, a multikinase inhibitor has shown modest efficacy in advanced hepatocellular carcinoma additional treatments are highly needed. Protein phosphorylation via kinases is a...
Autores principales: | Pott, Leona L, Hagemann, Sascha, Reis, Henning, Lorenz, Kristina, Bracht, Thilo, Herold, Thomas, Skryabin, Boris V, Megger, Dominik A, Kälsch, Julia, Weber, Frank, Sitek, Barbara, Baba, Hideo A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355317/ https://www.ncbi.nlm.nih.gov/pubmed/28060762 http://dx.doi.org/10.18632/oncotarget.14447 |
Ejemplares similares
-
Identification of Novel Biomarker Candidates for the Immunohistochemical Diagnosis of Cholangiocellular Carcinoma
por: Padden, Juliet, et al.
Publicado: (2014) -
Control of eukaryotic transcription elongation
por: Winston, Fred
Publicado: (2001) -
Proteome Analyses of Hepatocellular Carcinoma
por: Megger, Dominik A., et al.
Publicado: (2014) -
Inhibition of Eukaryotic Translation Elongation by Cycloheximide and Lactimidomycin
por: Schneider-Poetsch, Tilman, et al.
Publicado: (2010) -
Deciphering of the Human Interferon-Regulated Proteome by Mass Spectrometry-Based Quantitative Analysis Reveals Extent and Dynamics of Protein Induction and Repression
por: Megger, Dominik A., et al.
Publicado: (2017)